Comparative Pharmacology
Head-to-head clinical analysis: DALGAN versus MEPERGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALGAN versus MEPERGAN.
DALGAN vs MEPERGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Meperidine is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia. Promethazine is a phenothiazine antipsychotic that antagonizes histamine H1, dopamine D2, muscarinic acetylcholine, and alpha-adrenergic receptors, providing sedation and antiemetic effects.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
Meperidine 50-100 mg and promethazine 25-50 mg IM/IV every 3-4 hours as needed. Maximum meperidine dose: 600 mg/day.
None Documented
None Documented
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Meperidine: 3-4 hours (terminal; increased in hepatic impairment). Promethazine: 9-16 hours (terminal; prolonged in elderly).
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Renal elimination of metabolites (meperidine: ~90% as metabolites, <5% unchanged; promethazine: ~70-80% as metabolites, <1% unchanged). Biliary/fecal excretion is minimal (<10% for both).
Category C
Category C
Opioid Analgesic
Opioid Analgesic/Antiemetic Combination